Top 10 Richest Pharmaceutical Companies by Revenue (2025)

The global pharmaceutical industry is one of the most vital sectors in modern healthcare, responsible for producing life-saving drugs, vaccines, and medical treatments. In this article, we rank the top 10 richest pharmaceutical companies by revenue in 2025, showcasing the companies that generate the highest sales worldwide—across North America, Europe, and Asia.

In the pharmaceutical world, revenue not only reflects product sales but also highlights a company’s R&D strength, market penetration, regulatory approvals, and global healthcare partnerships. Companies with high revenue often have strong patent portfolios, diversified pipelines, and a solid presence in both prescription drugs and over-the-counter (OTC) healthcare. This list includes traditional pharmaceutical giants as well as vertically integrated healthcare retailers who now dominate in both medications and delivery channels.

Top 10 Richest Pharmaceutical Companies by Revenue (2025)

CVS Health (USA): $372.80 billion
Walgreens Boots Alliance (USA): $151.94 billion
Johnson & Johnson (USA): $89.33 billion
Sinopharm (China): $84.39 billion
Roche (Switzerland): $69.07 billion
Merck & Co. (USA): $64.16 billion
Pfizer (USA): $63.62 billion
AbbVie (USA): $56.33 billion
AstraZeneca (UK): $54.07 billion
Novartis (Switzerland): $51.72 billion

CVS Health leads the pharmaceutical industry not just as a drugstore chain, but as a vertically integrated healthcare company. With massive retail operations, insurance services through Aetna, and a major role in prescription distribution, it tops the list with over $370 billion in revenue.

Walgreens Boots Alliance follows, benefiting from its global retail presence and pharmacy services across the United States and Europe. These companies highlight a major shift—where pharmaceutical retail and healthcare delivery are merging into powerful hybrid models.

Among the traditional pharmaceutical manufacturers, Johnson & Johnson remains a dominant force with diverse offerings across pharmaceuticals, medical devices, and consumer health. China’s Sinopharm secures a top-four spot, supported by state-backed distribution of drugs, vaccines, and health products throughout Asia.

Roche, Merck, Pfizer, and AbbVie reflect the power of biotech innovation, with strong revenue from treatments for oncology, immunology, infectious diseases, and vaccines. Pfizer, notably, remains a global name following its role in developing COVID-19 vaccines.

AstraZeneca and Novartis, both based in Europe, continue to grow revenue through successful oncology pipelines, rare disease treatments, and biologic therapies—demonstrating that R&D-focused companies are still competitive with diversified healthcare giants.

#	Company Name	Revenue	Country
1	CVS Health	$372.80 Billion	USA
2	Walgreens Boots Alliance	$151.94 Billion	USA
3	Johnson & Johnson	$89.33 Billion	USA
4	Sinopharm	$84.39 Billion	China
5	Roche	$69.07 Billion	Switzerland
6	Merck	$64.16 Billion	USA
7	Pfizer	$63.62 Billion	USA
8	AbbVie	$56.33 Billion	USA
9	AstraZeneca	$54.07 Billion	UK
10	Novartis	$51.72 Billion	Switzerland

Disclaimer: The revenue figures in this article are based on publicly available data as of May 2025 and are subject to change due to market fluctuations and company performance.

Retail-Pharma Integration is Reshaping the Industry

A significant trend in the industry is the rise of pharmacy-led healthcare models, where companies like CVS Health and Walgreens are offering clinical services, insurance, and prescription fulfillment—all under one roof. This hybrid approach is rapidly increasing both revenue and influence, transforming how patients access care and medications.

Source

CompaniesMarketCap – Top publicly traded pharmaceutical companies by revenue